Vertex Pharmaceuticals Incorporated (VRTX)
NASDAQ: VRTX · Real-Time Price · USD
508.99
-2.75 (-0.54%)
Mar 25, 2025, 4:00 PM EST - Market closed
Vertex Pharmaceuticals Revenue
In the year 2024, Vertex Pharmaceuticals had annual revenue of $11.02B with 11.66% growth. Vertex Pharmaceuticals had revenue of $2.91B in the quarter ending December 31, 2024, with 15.66% growth.
Revenue (ttm)
$11.02B
Revenue Growth
+11.66%
P/S Ratio
11.91
Revenue / Employee
$1,806,574
Employees
6,100
Market Cap
130.72B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 11.02B | 1.15B | 11.66% |
| Dec 31, 2023 | 9.87B | 938.50M | 10.51% |
| Dec 31, 2022 | 8.93B | 1.36B | 17.91% |
| Dec 31, 2021 | 7.57B | 1.37B | 22.06% |
| Dec 31, 2020 | 6.21B | 2.04B | 49.08% |
| Dec 31, 2019 | Pro | Pro | Pro |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
VRTX News
- 14 days ago - Stocks beating the stock market's recent Trump slump have this in common - Market Watch
- 14 days ago - Top 3 Health Care Stocks That May Keep You Up At Night In Q1 - Benzinga
- 15 days ago - Vertex Pharmaceuticals Incorporated (VRTX) Leerink's Global Healthcare Conference 2025 (Transcript) - Seeking Alpha
- 18 days ago - Vertex Announces UK MHRA Approval of ALYFTREK® (Deutivacaftor/Tezacaftor/Vanzacaftor), a Once-Daily Next-in-Class CFTR Modulator for the Treatment of Cystic Fibrosis - Business Wire
- 19 days ago - Vertex Pharmaceuticals: Company Passes My Health Check With Flying Colors, Upholding Buy Rating - Seeking Alpha
- 22 days ago - Vertex Pharmaceuticals Incorporated (VRTX) TD Cowen 45th Annual Health Care Conference (Transcript) - Seeking Alpha
- 25 days ago - Vertex Receives CHMP Positive Opinion for Expanded Label for KAFTRIO® in Combination With Ivacaftor for People With Cystic Fibrosis to Include Rare Mutations - Business Wire
- 5 weeks ago - Vertex to Participate in Upcoming March Investor Conferences - Business Wire